Last reviewed · How we verify
Ropivacaine 0.75% Injectable Solution
Ropivacaine 0.75% Injectable Solution is a Small molecule drug developed by Paola M Zamora Munoz. It is currently FDA-approved. Also known as: parecoxib 40mg, ROPIN 0.75%, Alone, Ropivacaine.
Ropivacaine 0.75% Injectable Solution is a small molecule used for pain management, including postoperative pain, and has been studied in various clinical trials for its effectiveness in conditions such as post-thoracotomy pain and pain associated with neurosurgery, unplanned caesarean section, anorectal surgery, and other procedures. It is administered through methods such as erector spinae plane block, intercostal nerve block, and scalp blocks.
At a glance
| Generic name | Ropivacaine 0.75% Injectable Solution |
|---|---|
| Also known as | parecoxib 40mg, ROPIN 0.75%, Alone, Ropivacaine |
| Sponsor | Paola M Zamora Munoz |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cryoablation of Intercostal Nerves for Pain Management in Early Postoperative Period in Patients With Minimally Invasive Mitral Valve Surgery (NA)
- A Multidisciplinary Perioperative Pain Management (NA)
- Efficacy of Methylene Blue Plus Ropivacaine for Post-Hemorrhoidectomy Pain. (PHASE4)
- Chloroprocaine 1% Versus Ropivacaine 0,75% During Cesarean Section (NA)
- Comparison of Continuous ESP Versus TEA After Thoracotomy (NA)
- Combining Lidocaine and Ropivacaine for an Infraclavicular Brachial Plexus Nerve Block (PHASE3)
- "Comparison of Intra-articular of 0.2% Ropivacaine vs. 0.75% Ropivacaine in Postoperative of Knee Arthroscopy" (PHASE4)
- Comparing Two Regional Anesthesia Interventions for Knee Arthroplasty. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine 0.75% Injectable Solution CI brief — competitive landscape report
- Ropivacaine 0.75% Injectable Solution updates RSS · CI watch RSS
- Paola M Zamora Munoz portfolio CI
Frequently asked questions about Ropivacaine 0.75% Injectable Solution
What is Ropivacaine 0.75% Injectable Solution?
Who makes Ropivacaine 0.75% Injectable Solution?
Is Ropivacaine 0.75% Injectable Solution also known as anything else?
What development phase is Ropivacaine 0.75% Injectable Solution in?
Related
- Manufacturer: Paola M Zamora Munoz — full pipeline
- Also known as: parecoxib 40mg, ROPIN 0.75%, Alone, Ropivacaine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing